Aktienanalyse zu Arvinas Inc (ARVN)ARVNArvinas Inc

Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Arvinas Inc (ARVN) is not a good buy. The stock is trading at $6.97, significantly below its recent analyst price targets, which range from $10 to $21. The RSI is at 35.88, indicating that the stock is oversold, but the negative momentum in the stock's price, down 39.23% year-to-date, raises concerns. Additionally, insider selling has increased by 504.89%, signaling a lack of confidence from those closest to the company. While there are potential future revenue opportunities from FDA approvals and licensing deals, the current financial instability, including a net income loss of $57.6 million in Q1 2026, poses a significant risk.

3 analysts cover ARVN: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 16.00.